Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | PPARA | Q07869 | 3/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19361664 | 0.82 | TSHR (0.33) | TSHRALDH1A1CYP3A4TDP1 | |
| SCHEMBL28178492 | 0.80 | TSHR (0.36) | TSHRALDH1A1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23943462 | 0.80 | TSHR (0.32) | TSHRCYP3A4TDP1 | |
| SCHEMBL7132864 | 0.78 | TSHR (0.33) | TSHRALDH1A1CYP3A4 | |
| SCHEMBL21930110 | 0.78 | PPARG (0.31) | PPARAPPARG | |
| SCHEMBL4119963 | 0.78 | DGAT1 (0.34) | TSHRALDH1A1CYP2C19TDP1MAPT | |
| SCHEMBL15105913 | 0.77 | TSHR (0.35) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL10521805 | 0.77 | TSHR (0.34) | TSHRPPARAPPARGMEN1CYP1A2 | |
| SCHEMBL9777708 | 0.76 | CYP3A4 (0.33) | TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL29141109 | 0.76 | BTN3A1 (0.34) | TSHRPPARAPPARGALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8283793-A | — | — | None | — | — | JP | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230357275-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357275-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357275-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230212191-A1 | SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| EP-4149947-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | Prelude Therapeutics, Incorporated (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115698024-A | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia 1 (MCL-1) protein | 普莱鲁德疗法有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-104781261-B | The macrocyclic hcv inhibitors of flaviviridae | 吉利德科学公司 | 2017-08-25 | — | — | CN | disclosed |
| CN-104781261-A | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES INC | 2015-07-15 | — | — | CN | disclosed |
| EP-1016698-B1 | Use of a solvent composition containing an oxyisobutyric acid ester as a solvent in coatings, adhesives and printing inks | MITSUBISHI RAYON CO (JP) | 2004-09-22 | — | — | EP | disclosed |
| EP-0629671-B1 | Solvent composition | MITSUBISHI RAYON CO (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-1016699-A1 | Use of a solvent composition comprising an oxyisobutyric acid ester as a cleaning agent | Mitsubishi Rayon Co., Ltd. (JP) | 2000-07-05 | — | — | EP | disclosed |
| EP-1016698-A1 | Use of a solvent composition containing an oxyisobutyric acid ester as a solvent in coatings, adhesives and printing inks | Mitsubishi Rayon Co., Ltd. (JP) | 2000-07-05 | — | — | EP | disclosed |
| US-5630945-A | RECOVERING STYRENE, POLYESTER AND ACRYLIC RESIN FROM WASTE AS A SOLUTION AND RECOVERING SOLVENT WITH OXYISOBUTYRIC ACID ESTER | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-05-20 | — | — | US | disclosed |
| US-5612303-A | HYDROXY OR ETHERIFIED ESTERS | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-03-18 | — | — | US | disclosed |
| JP-H08283793-A | CLEANING AGENT FOR INK | NITTO CHEM IND CO LTD | 1996-10-29 | — | — | JP | disclosed |
| EP-0629671-A2 | Solvent composition | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212191-A1 | SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | MCL1, BCL9, BCL2L1 | TSHR 4537/4885PPARA 3200/4885PPARG 3460/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | TSHR 1815/4885PPARA 2993/4885PPARG 2185/4885 |
| US-20230357275-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | MCL1, BCL2A1, BCL2L1 | TSHR 4477/4885PPARA 2092/4885PPARG 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.